Hualan Biological Vaccine Inc. (SHE:301207)
China flag China · Delayed Price · Currency is CNY
19.25
-0.01 (-0.05%)
Apr 29, 2026, 3:04 PM CST

Hualan Biological Vaccine Company Description

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China.

The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine.

It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines.

In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.

Hualan Biological Vaccine Inc.
Country China
Founded 2005
Industry Biotechnology
Sector Healthcare
Employees 708
CEO Wenjue An

Contact Details

Address:
Jia No. 1-1, Hualan Avenue
Xinxiang, 453003
China
Phone 86 37 3355 9909
Website hualanbacterin.com

Stock Details

Ticker Symbol 301207
Exchange Shenzhen Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number CNE1000058J9
SIC Code 2836

Key Executives

Name Position
Wenjue An GM and Director
Ruowen Pan Executive Vice President and Director
Ke Lu Chief Financial Officer and Secretary